Cencora’s second quarter was marked by performance that met Wall Street’s expectations on revenue and exceeded consensus on non-GAAP profitability, driving a positive market response. Management credited execution in specialty pharmaceuticals, especially through its Management Services Organizations (MSOs) like OneOncology and RCA, as a core driver of growth, while digital transformation initiatives improved operational efficiency. CEO Robert Mauch highlighted the company’s unique positioning in specialty care, stating, “Our specialty platform supports growth across the healthcare ecosystem.”
Is now the time to buy COR? Find out in our full research report (it’s free for active Edge members).
Cencora (COR) Q2 CY2026 Highlights:
- Revenue: $84.75 billion vs analyst estimates of $84.43 billion (5.1% year-on-year growth, in line)
- Adjusted EPS: $4.48 vs analyst estimates of $4.35 (3% beat)
- Management slightly raised its full-year Adjusted EPS guidance to $17.85 at the midpoint
- Operating Margin: 1.3%, in line with the same quarter last year
- Market Capitalization: $63.71 billion
While we enjoy listening to the management’s commentary, our favorite part of earnings calls is the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions From Cencora’s Q2 Earnings Call
- Lisa Gill (JPMorgan) asked about the drivers of reacceleration in the U.S. pharma business. CFO Eva Boratto pointed to MSO strength and specialty segment growth, while CEO Robert Mauch reiterated confidence in long-term guidance.
- Glen Santangelo (Barclays) pressed for distinctions between Part B and Part D biosimilars. Mauch explained that Part B biosimilars present greater profit opportunities due to the company’s service intensity in infusion settings.
- Elizabeth Anderson (Evercore ISI) questioned the sustainability of above-average growth at OneOncology. Mauch described MSO integration as on track and outlined phases for future value creation, including expanded clinical trial services.
- George Hill (Deutsche Bank) inquired about increased competition in specialty logistics. Mauch emphasized Cencora’s pharmaceutical-centric differentiation and robust capabilities in high-end logistics for clinical trials.
- Kevin Caliendo (UBS) asked about risks from proposed ASP rule changes. Mauch indicated management is closely monitoring policy developments but expects physician reimbursement to remain protected under current proposals.
Catalysts in Upcoming Quarters
In coming quarters, our team will watch (1) the pace of integration and organic growth in MSO platforms like OneOncology and RCA, (2) tangible progress in digital transformation initiatives such as AI-driven demand forecasting, and (3) updates on regulatory developments affecting biosimilars and the 340B program. Execution on tuck-in acquisitions and expansion of clinical trial capabilities will also be key signposts.
Cencora currently trades at $331.45, up from $306.28 just before the earnings. In the wake of this quarter, is it a buy or sell? See for yourself in our full research report (it’s free).
High-Quality Stocks for All Market Conditions
WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don’t just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.
But our AI platform says the party isn’t over. Find out which 9 stocks made the cut this week — FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+1,154% between June 2020 and June 2025). Find your next big winner with StockStory today.
